Plus Therapeutics Net Income
| PSTV Stock | USD 0.26 0.03 13.04% |
As of the 8th of February, Plus Therapeutics holds the Risk Adjusted Performance of (0.08), variance of 51.64, and Coefficient Of Variation of (954.32). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Plus Therapeutics, as well as the relationship between them. Please check Plus Therapeutics market risk adjusted performance and treynor ratio to decide if Plus Therapeutics is priced some-what accurately, providing market reflects its current price of 0.26 per share. As Plus Therapeutics appears to be a penny stock we also advise to check out its jensen alpha numbers.
Plus Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 18.192 | Revenue | Earnings Share (0.96) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -11.7 M | -12.3 M | |
| Net Loss | -14.9 M | -15.7 M | |
| Net Loss | -23.3 M | -24.5 M | |
| Net Loss | (2.25) | (2.36) | |
| Net Income Per E B T | 2.98 | 3.13 |
Plus | Net Income | Build AI portfolio with Plus Stock |
The evolution of Net Income for Plus Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Plus Therapeutics compares to historical norms and industry peers.
Latest Plus Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Plus Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Plus Therapeutics financial statement analysis. It represents the amount of money remaining after all of Plus Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Plus Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Plus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (12.98 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Plus Net Income Regression Statistics
| Arithmetic Mean | (18,206,789) | |
| Coefficient Of Variation | (52.59) | |
| Mean Deviation | 7,808,434 | |
| Median | (13,399,000) | |
| Standard Deviation | 9,575,224 | |
| Sample Variance | 91.7T | |
| Range | 35.3M | |
| R-Value | 0.48 | |
| Mean Square Error | 75.7T | |
| R-Squared | 0.23 | |
| Significance | 0.05 | |
| Slope | 901,787 | |
| Total Sum of Squares | 1467T |
Plus Net Income History
Other Fundumenentals of Plus Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Plus Therapeutics Net Income component correlations
Plus Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Plus Therapeutics is extremely important. It helps to project a fair market value of Plus Stock properly, considering its historical fundamentals such as Net Income. Since Plus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Plus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Plus Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
What growth prospects exist in Biotechnology sector? Can Plus capture new markets? Factors like these will boost the valuation of Plus Therapeutics. Anticipated expansion of Plus directly elevates investor willingness to pay premium valuations. Valuation analysis balances hard financial data with qualitative growth assessments. While each Plus Therapeutics valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Earnings Share (0.96) | Revenue Per Share | Quarterly Revenue Growth (0.04) | Return On Assets | Return On Equity |
The market value of Plus Therapeutics is measured differently than its book value, which is the value of Plus that is recorded on the company's balance sheet. Investors also form their own opinion of Plus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Plus Therapeutics' true underlying value. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. Because Plus Therapeutics' market value can be influenced by many factors that don't directly affect Plus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Plus Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Plus Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Plus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Plus Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Plus Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Plus Therapeutics.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in Plus Therapeutics on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding Plus Therapeutics or generate 0.0% return on investment in Plus Therapeutics over 90 days. Plus Therapeutics is related to or competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, and Lipocine. Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercia... More
Plus Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Plus Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Plus Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 48.3 | |||
| Value At Risk | (8.82) | |||
| Potential Upside | 9.43 |
Plus Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Plus Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Plus Therapeutics' standard deviation. In reality, there are many statistical measures that can use Plus Therapeutics historical prices to predict the future Plus Therapeutics' volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (1.00) | |||
| Total Risk Alpha | (1.47) | |||
| Treynor Ratio | (0.26) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Plus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Plus Therapeutics February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.25) | |||
| Mean Deviation | 4.97 | |||
| Coefficient Of Variation | (954.32) | |||
| Standard Deviation | 7.19 | |||
| Variance | 51.64 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (1.00) | |||
| Total Risk Alpha | (1.47) | |||
| Treynor Ratio | (0.26) | |||
| Maximum Drawdown | 48.3 | |||
| Value At Risk | (8.82) | |||
| Potential Upside | 9.43 | |||
| Skewness | (2.02) | |||
| Kurtosis | 10.39 |
Plus Therapeutics Backtested Returns
Plus Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.13, which implies the firm had a -0.13 % return per unit of risk over the last 3 months. Plus Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Plus Therapeutics' Variance of 51.64, risk adjusted performance of (0.08), and Coefficient Of Variation of (954.32) to confirm the risk estimate we provide. The company holds a Beta of 2.92, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Plus Therapeutics will likely underperform. At this point, Plus Therapeutics has a negative expected return of -0.93%. Please make sure to check Plus Therapeutics' value at risk and rate of daily change , to decide if Plus Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.78 |
Almost perfect reverse predictability
Plus Therapeutics has almost perfect reverse predictability. Overlapping area represents the amount of predictability between Plus Therapeutics time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Plus Therapeutics price movement. The serial correlation of -0.78 indicates that around 78.0% of current Plus Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.78 | |
| Spearman Rank Test | -0.59 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Plus Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Plus Therapeutics reported net income of (12.98 Million). This is 103.8% lower than that of the Biotechnology sector and 118.53% lower than that of the Health Care industry. The net income for all United States stocks is 102.27% higher than that of the company.
Plus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Plus Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Plus Therapeutics could also be used in its relative valuation, which is a method of valuing Plus Therapeutics by comparing valuation metrics of similar companies.Plus Therapeutics is currently under evaluation in net income category among its peers.
Plus Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Plus Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Plus Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Plus Therapeutics' value.| Shares | Atlantic Union Bankshares Corp | 2025-06-30 | 500 | Wells Fargo & Co | 2025-06-30 | 357 | Tradewinds Capital Management, Llc | 2025-06-30 | 200 | Bank Of America Corp | 2025-06-30 | 158 | Advisor Group Holdings, Inc. | 2025-06-30 | 133 | Jones Financial Companies Lllp | 2025-06-30 | 26.0 | Susquehanna International Group, Llp | 2025-06-30 | 0.0 | Aigh Capital Management, Llc | 2025-03-31 | 0.0 | Barclays Plc | 2025-06-30 | 0.0 | Jane Street Group Llc | 2025-06-30 | 117.5 K | Ubs Group Ag | 2025-06-30 | 87.6 K |
Plus Fundamentals
| Return On Equity | -5.22 | ||||
| Return On Asset | -0.66 | ||||
| Operating Margin | (3.21) % | ||||
| Current Valuation | 29.01 M | ||||
| Shares Outstanding | 178.37 M | ||||
| Shares Owned By Insiders | 1.15 % | ||||
| Shares Owned By Institutions | 9.65 % | ||||
| Number Of Shares Shorted | 11.36 M | ||||
| Price To Book | 9.02 X | ||||
| Price To Sales | 8.82 X | ||||
| Revenue | 5.82 M | ||||
| Gross Profit | (2.37 M) | ||||
| EBITDA | (8.4 M) | ||||
| Net Income | (12.98 M) | ||||
| Cash And Equivalents | 20.27 M | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 3.37 M | ||||
| Debt To Equity | 0.53 % | ||||
| Current Ratio | 2.81 X | ||||
| Book Value Per Share | 0.04 X | ||||
| Cash Flow From Operations | (10.55 M) | ||||
| Short Ratio | 1.23 X | ||||
| Earnings Per Share | (0.96) X | ||||
| Target Price | 5.5 | ||||
| Number Of Employees | 21 | ||||
| Beta | 0.85 | ||||
| Market Capitalization | 46.36 M | ||||
| Total Asset | 6.63 M | ||||
| Retained Earnings | (493.48 M) | ||||
| Working Capital | (10.29 M) | ||||
| Net Asset | 6.63 M |
About Plus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Plus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Plus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Plus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.